Cerebral infarction and transient ischaemic attack Circulatory System Cerebral infarction
Conditions
Interventions
One year course of allopurinol (oral) 300 mg per day or placebo.
Details of Joint Sponsor:
University of Glasgow
University Avenue
Glasgow G12 8QQ
United Kingdom
Sponsors
NHS Greater Glasgow and Clyde (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, aged over 18 2. Ischaemic Stroke (including transient ischaemic attack [TIA] where symptoms last less than 24 hours) 3. Brain imaging not suggestive of an alternative diagnosis 4. Randomisation within one year of ictus
Exclusion criteria
Exclusion criteria: 1. >70% extra-cranial internal carotid artery stenosis 2. Significant co-morbidity or frailty likely to cause death within 12 months or likely to make adherence to study protocol difficult for participant 3. Contra-indication to or indication for administration of allopurinol 4. Concurrent azathioprine or 6-mercaptopurine therapy 5. Significant hepatic impairment (defined as serum bilirubin, aspartate aminotransferase [AST] or alanine aminotransferase [ALT] greater than three times upper limit of normal [ULN]) 6. Estimated glomerular filtration rate <50 mls/min 7. Cognitive impairment deemed sufficient to compromise capacity to consent or to comply with the protocol 8. Women of childbearing potential 9. Prisoners
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in carotid intima-media thickness over a one year period (intima-media thickness [IMT] progression rate). | — |
Secondary
| Measure | Time frame |
|---|---|
| The following will be assessed at baseline, 6 and 12 months: 1. Levels of endothelial progenitor cells (EPCs) and circulating markers of endothelial function 2. Number of adverse events | — |
Countries
United Kingdom
Outcome results
None listed